IRIS
TONIUTTO, Pierluigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.938
EU - Europa 3.939
AS - Asia 2.490
SA - Sud America 349
AF - Africa 34
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 4
Totale 20.774
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.810
SG - Singapore 1.240
UA - Ucraina 1.051
DE - Germania 749
CN - Cina 730
IT - Italia 394
FI - Finlandia 365
RU - Federazione Russa 328
BR - Brasile 319
SE - Svezia 309
IE - Irlanda 236
TR - Turchia 207
FR - Francia 203
GB - Regno Unito 122
KR - Corea 97
CA - Canada 95
HK - Hong Kong 50
IN - India 44
BE - Belgio 43
IR - Iran 36
PL - Polonia 31
AT - Austria 30
VN - Vietnam 25
EU - Europa 19
MX - Messico 19
NL - Olanda 13
CZ - Repubblica Ceca 11
AR - Argentina 9
ES - Italia 9
TG - Togo 9
ZA - Sudafrica 9
IQ - Iraq 8
CH - Svizzera 6
AZ - Azerbaigian 5
BD - Bangladesh 5
EE - Estonia 5
JP - Giappone 5
LT - Lituania 5
PK - Pakistan 5
UZ - Uzbekistan 5
VE - Venezuela 5
CL - Cile 4
DZ - Algeria 4
MA - Marocco 4
AO - Angola 3
BG - Bulgaria 3
BN - Brunei Darussalam 3
CO - Colombia 3
CR - Costa Rica 3
DK - Danimarca 3
EG - Egitto 3
KG - Kirghizistan 3
LI - Liechtenstein 3
NO - Norvegia 3
PA - Panama 3
PE - Perù 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AU - Australia 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
GR - Grecia 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
PY - Paraguay 2
RO - Romania 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AL - Albania 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CY - Cipro 1
EC - Ecuador 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KH - Cambogia 1
LU - Lussemburgo 1
ME - Montenegro 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 20.774
Salva come PNG Salva come JPEG
Città #
Fairfield 1.862
Woodbridge 1.800
Ann Arbor 1.043
Houston 1.006
Chandler 1.002
Ashburn 845
Seattle 765
Wilmington 737
Jacksonville 704
Cambridge 637
Singapore 612
Dearborn 463
Beijing 353
Boardman 312
Princeton 229
Udine 226
Dublin 223
Munich 192
Izmir 173
Helsinki 108
San Diego 87
Seoul 84
Ottawa 67
New York 52
Des Moines 49
Hong Kong 48
Los Angeles 48
Brussels 39
Hefei 36
Norwalk 35
Nuremberg 34
Ogden 34
Kunming 33
Falls Church 30
Nanjing 28
Warsaw 26
Leawood 25
Dong Ket 21
Frankfurt am Main 21
Guangzhou 20
São Paulo 20
Düsseldorf 17
San Mateo 17
Shanghai 17
Vienna 17
Zanjan 16
Jinan 15
Mexico City 14
San Francisco 14
Washington 14
Zhengzhou 14
Chongqing 13
Toronto 13
Augusta 12
Belluno 12
Grafing 11
Hebei 11
Milan 11
Nanchang 11
Trieste 11
Phoenix 10
Wuhan 10
Ardabil 9
Dallas 9
Fuzhou 9
Hangzhou 9
Lomé 9
London 9
Mumbai 9
San Jose 9
Turku 9
Andover 8
Belo Horizonte 8
Chengdu 8
Monmouth Junction 8
Seongnam 8
Brno 7
Changsha 7
Guarulhos 7
Indiana 7
Jyväskylä 7
Lauterbourg 7
Portsmouth 7
Shenyang 7
Brooklyn 6
Ningbo 6
Rio de Janeiro 6
Stockholm 6
Amsterdam 5
Baghdad 5
Baku 5
Edinburgh 5
Goiânia 5
Istanbul 5
Recife 5
Redmond 5
Santa Clara 5
Tallinn 5
Tashkent 5
Tokyo 5
Totale 14.670
Salva come PNG Salva come JPEG
Nome #
Deficient antithrombin III activity and enhanced fibrinolysis in patients with liver disease: Evidence against a cause-effect relationship 200
Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. 194
Skills and requirements of a transplant hepatologist: board certification of the Italian Association for the Study of the Liver (AISF). 189
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C 182
Increase of Serum aú1-Acid Glycoprotein Despite the Decline of Liver Synthetic Function in Cirrhotics with Hepatocellular Carcinoma 182
Steatosis of the graft is a risk factor for posttransplantation biliary complications. 178
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 175
LONG-TERM OUTCOMES OF ORTHOTOPIC LIVER TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS AND COMPARISON WITH HUMAN IMMUNODEFICIENCY VIRUS-NEGATIVE CASES 174
Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. 173
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study 170
A single-center experience of late retransplantation of the liver. 164
Intensity of inflammatory damage and serum lipid peroxide concentrations in liver disease 161
Management of infections in cirrhotic patients: report of a consensus conference. 159
The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. 157
Association between the epidermal growth factor rs4444903 G/G genotype and advanced fibrosis at a young age in chronic hepatitis C. 156
Toll Like Receptor 4 D299G Associates with Disease Progression in Caucasian Patients with Chronic HBV Infection: Relationship with Gender. 154
PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis 152
Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. 151
Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. 151
Association between vitamin D receptor genetic polymorphisms and acute cellular rejection in liver-transplanted patients. 150
Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. 148
Mild sialoadenitis: a common finding in patients with hepatitis C virus infection 144
A comparison of four serum markers of fibrosis in the diagnosis of cirrhosis 141
Liver transplantation from old donors into HCV and non-HCV recipients 141
Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. 139
Circulating intercellular adhesion molecule-1 (cICAM-1) concentration in liver disease. Relationship with cholestasis and functioning hepatic mass. 139
Splenic Artery Syndrome as a Possible Cause of Late Onset Refractory Ascites after Liver Transplantation: Management with Proximal Splenic Artery Embolization 138
Early activation of interferon-stimulated genes in human liver allografts: relationship with acute rejection and histological outcome. 133
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. 133
Consensus conference on TIPS management: Techniques, indications, contraindications 132
Specific issues concerning the management of patients on the waiting list and after liver transplantation 132
Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients 132
Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. 131
Genetic polymorphisms of vitamin D pathway predict antiviral treatment outcome in slow responder naïve patients with chronic hepatitis C. 131
Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy 131
DIFFUSION-WEIGHTED MRI IN EVALUATING LIVER FIBROSIS: A FEASIBILITY STUDY IN CIRRHOTIC PATIENTS 130
Hepatic release of erythropoietin induced by transarterial chemoembolization in patients with hepatocellular carcinoma. 129
DE NOVO TUMORS ARE A MAJOR CAUSE OF LATE MORTALITY AFTER ORTHOTOPIC LIVER TRANSPLANTATION 129
Acute alcoholic hepatitis and liver transplantation: Waiting for Godot 129
Degree of bile-duct dilatation in liver-transplanted patients with biliary stricture: a magnetic resonance cholangiography-based study. 128
Diagnostic usefulness of acute-phase protein measurement in hepatocellular carcinoma. 127
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 127
Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. 126
Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases 126
Clinical and virologic response to entecavir in HBV related chronic hepatitis or cirrhosis: data from the clinical practice in a single centre cohort. 125
Genetic polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic hepatitis C 124
Safety and efficacy of splenic artery embolization for portal hyperperfusion in liver transplant recipients: A 5-year experience 124
Biliary strictures after liver transplantation: Role of interleukin 28B genotypes in cyclosporine treated 123
Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment 122
STEATOSIS OF THE HEPATIC GRAFT AS A RISK FACTOR FOR POST-TRANSPLANT BILIARY COMPLICATIONS 120
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. 120
Recipient perioperative cholesterolaemia and graft cholesterol metabolism gene expression predict liver transplant outcome. 119
Quality-of-life assessment before and after liver transplantation. 119
Predictors of endoscopic treatment outcome in the management of biliary complications after orthotopic liver transplantation 119
Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis 118
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 118
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 118
Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease associated with increased circulating levels of adhesion molecules. 118
Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection. 118
Expression of the interferon-inducible proteins MxA and IFI16 in liver allografts. 117
Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation 117
Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C 115
Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation 115
Favourable Outcome of Adefovir-Dipivoxil Treatment in Acute de Novo Hepatitis B After Liver Transplantation 115
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial 115
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases 115
Increased serum phospholipase A2 activity in advanced chronic liver disease as an expression of the acute phase response. 115
Antiviral treatment of hepatitis C 115
Low fibrosis progression of recurrent hepatitis C in apolipoprotein E e4 carriers: relationship with the blood lipid profile 115
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship. 114
Impact of magnetic resonance cholangiography in managing liver-transplanted patients: preliminary results of a clinical decision-making study 114
Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study. 114
Vitamin D deficiency and HCV chronic infection: what comes first? 113
Evidence for a multifactorial control of serum erythropoietin concentration in liver disease 113
HUMAN LEUKOCYTE ANTIGEN POLYMORPHISMS IN ITALIAN PRIMARY BILIARY CIRRHOSIS: A MULTICENTER STUDY OF 664 PATIENTS AND 1992 HEALTHY CONTROLS 113
Genetic polymorphism at the apolipoprotein E locus affects the outcome of chronic hepatitis B 113
Anti-envelope antibodies in anti-hepatitis C virus (HCV) positive patients with and without liver disease 113
Prevalence and risk factors for delayed adrenal insufficiency after liver transplantation 112
Weight gain after liver transplantation and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene 112
OCCULT HEPATITIS B VIRUS INFECTION IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HEPATITIS C: RELATIONSHIP WITH DONOR AGE AND FIBROSIS PROGRESSION 112
GENE POLYMORPHISM AT THE INTERLEUKIN 6 -174 G > C LOCUS AFFECTS THE OUTCOME OF CHRONIC HEPATITIS B 112
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. 112
Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end stage liver disease 112
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 111
Steatosis of the hepatic graft as a risk factor for post-transplant biliary complications 110
Successful minimally invasive management of late portal vein thrombosis after splenectomy due to splenic artery steal syndrome following liver transplantation: a case report 110
INFLUENCE OF ANGIOTENSIN-CONVERTING ENZYME I/D GENE POLYMORPHISM ON CLINICAL AND HISTOLOGICAL CORRELATES OF CHRONIC HEPATITIS C 110
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 109
Occult hepatitis B virus infection in peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. 109
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. 108
IgM antibody response to the hepatitis C virus core protein in intravenous drug users. 108
Antiviral treatment in patients with hepatitis C virus related cirrhosis awaiting liver transplantation 108
Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used. 107
Factors associated with serum HCV RNA positivity in anti HCV antibody positive intravenous drug users 107
Prevalence and impact on survival of occurrence of portal vein thrombosis in primary liver cancer 106
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 106
Common issues in the management of patients in the waiting list and after liver transplantation 106
Current challenges and future directions for liver transplantation 105
Relationship between vitamin D status and response to hepatitis C virus therapy 105
Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients 105
Totale 12.936
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.969
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.969
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020312 0 0 0 0 0 0 0 0 0 0 0 312
2020/20212.986 86 314 218 364 110 419 174 290 370 110 362 169
2021/20221.861 81 149 112 110 27 104 108 97 32 278 479 284
2022/20232.254 259 167 35 304 229 580 1 174 339 25 79 62
2023/2024674 132 78 32 18 138 97 15 33 58 38 10 25
2024/20253.553 100 289 145 172 141 311 304 339 570 361 743 78
Totale 21.260